Aslan and Bristol-Myers Squibb Enter Cancer Partnership

Bristol-Myers Squibb has signed an innovative strategic partnership with Aslan Pharmaceuticals, headquartered in Singapore, which will see Aslan help develop one of the US major’s investigational cancer compounds. The drug in question, BMS-777607, is a small molecule inhibitor of the MET receptor tyrosine kinase for the treatment of solid tumours. Under the terms of the

Continue Reading